← Leaderboards
Philip Lograsso
Stanford University
$2,264
Attributed
$2,264
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1K · FY2008–11$2K$1.5K$1K$500$0
'08
'09
'10
'11
Funding mix
By agency
NIH$2,264 · 4
By mechanism
P41$2,264 · 4
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Keith O Hodgson$40,099,114
- Quynh-Thu X Le$15,492,013
- Amato J. Giaccia$32,506,927
- Kenan Christopher Garcia$35,612,900
- William I Weis$26,357,228
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthCellsFundingGrantInhibitor/AntagonistMapk10 GeneMouse ModelNeuronsParkinson DiseaseProteinsResourcesSourceTranslationsBinding (Molecular Function)Mitogen-Activated Protein KinasesDesignEnzymesFamilyInstitutionResearch PersonnelMapk8 GeneStructureSpecificityPhosphotransferases
Grant awards (4)
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$559
P41 · FY2011 · RR · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$346
P41 · FY2010 · RR · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$213
P41 · FY2009 · RR · contact PI
DEVELOPMENT OF TYPE II INHIBITORS FOR JNK3$1,146
P41 · FY2008 · RR · contact PI